Genmab announces progress with Lundbeck collaboration

First pre-clinical milestone met in Lundbeck collaboration

19-Dec-2011 - Genmab A/S announced it had reached the first pre-clinical milestone in the collaboration with H. Lundbeck A/S, triggering a €1 million payment. Genmab has reached the first milestone in the collaboration with H. Lundbeck A/S to create and develop human antibody therapeutics for disorders of the ...

Genmab Announces Antibody Development Collaboration with Lundbeck

15-Oct-2010 - Genmab A/S announced an agreement to create and develop human antibody therapeutics for disorders of the central nervous system (CNS) with H. Lundbeck A/S. Genmab will create novel human antibodies to three targets identified by Lundbeck. Lundbeck will have access to Genmab’s antibody creation ...

Genmab Announces Results of Ofatumumab Phase II Study in Multiple Sclerosis

GSK and Genmab Announce Start of Ofatumumab Phase III Combination Study in Non-Hodgkin’s Lymphoma

14-Sep-2010 - Genmab A/S announced encouraging results from an ofatumumab Phase II safety and pharmacokinetics study in patients with relapsing-remitting multiple sclerosis (RRMS). A total of 38 patients were included in this double-blind, dose escalation trial. Patients were randomized to receive two ...

Genmab and Pepscan to identify human antibodies against intractable targets

05-Mar-2008 - Genmab A/S and Pepscan announced the start of a research collaboration aimed at identifying fully human monoclonal antibodies against intractable disease targets. Intractable targets include those that are difficult to address using commonly available technologies but are highly desirable for ...

Roche files IND for second Genmab antibody

14-Aug-2007 - Genmab A/S announced that its partner Roche has filed an Investigational New Drug application (IND) with the US Food and Drug Administration for a Genmab antibody developed under the companies' collaboration. Genmab will receive a milestone payment from Roche which does not influence Genmab's ...

GlaxoSmithKline and Genmab present positive Phase II results with Ofatumumab in patients with rheumatoid arthritis

18-Jun-2007 - GlaxoSmithKline (GSK) and Genmab A/S announced positive primary efficacy data (evaluated at 24 Weeks) to be presented at EULAR 2007, the Annual European Congress of Rheumatology from a Phase II study of ofatumumab (HuMax-CD20(R)) in patients with rheumatoid arthritis (RA). Ofatumumab is being ...

Genmab licenses MIF receptor target from cytokine pharmasciences

22-Nov-2006 - Genmab A/S and Cytokine PharmaSciences, Inc. announced that Genmab has licensed rights to the MIF receptor target from Cytokine PharmaSciences. Genmab intends to develop therapeutic human antibodies to the licensed target. Details of the agreement were not disclosed. "We are enthusiastic about ...

Roche files for Genmab Antibody

15-Dec-2005 - Genmab A/S announced that its partner Roche has filed an Investigational New Drug application (IND) with the US Food and Drug Administration for a Genmab antibody developed under the companies' collaboration. This is the ninth milestone Genmab has achieved under the agreement. Genmab will receive ...

Genmab Acquires Rights for 16 Cancer Targets

20-May-2005 - Genmab A/S announced that it has acquired rights to 16 potential targets to treat non-steroid dependent cancers of epithelial cell origin, such as gastrointestinal cancers, including colon cancer, from the insolvency administrator of Europroteome, AG, a privately owned German company currently in ...

Roche selects two Genmab antibodies as clinical candidates

22-Mar-2004 - Genmab A/S announced Roche has selected two Genmab antibodies as candidates for clinical development. The antibodies, developed under a collaboration between Roche and Genmab which began in May 2001, are each designed to target a different disease area. "The selection of these antibodies as ...